Xinteza Unveils Non-Cannabis Disruptive Source for Cannabinoid Biosynthesis in Groundbreaking Research Led by Professor Asaph Aharoni at the Weizmann Institute of Science
- Significantly expands IP portfolio of genes and enzymes related to cannabinoid synthesis
- Addresses known enzymatic and modification bottlenecks and challenges in biosynthesis
TEL AVIV, Israel, August 11, 2022 /PRNewswire/ — Xinteza API Ltd., an innovative biosynthesis technology company, today announced that it has expanded its intellectual property portfolio with the breakthrough discovery of a novel non-plant-derived production system from cannabis, capable of performing highly efficient and flawless end-to-end cannabinoid synthesis. The company’s intellectual property portfolio is under license signed with Yeda, the commercial arm of the Weizmann Institute of Science.
Unlike Cannabis Sativa, which produces cannabinoids only in its female flowering parts, the new expression system contains cannabinoid enzyme machinery throughout its mass of botanical tissue, and therefore has the potential to produce a higher active ingredient to biomass ratio. higher than cannabis plants.
“This discovery is a major step on the way to discovering and exploiting rare and novel cannabinoid molecules with potentially novel pharmacological activities,” said Prof. Asaph Aharoni, scientific co-founder of Xinteza and director of the plant metabolomics laboratory of the Weizmann Institute of Science and of the department of plant and environmental sciences of the Institute. “Furthermore, this non-Cannabaceae alternative production system is significantly more amenable than cannabis to genetic engineering and cell transformation, allowing for greater flexibility in a range of biosynthetic enhancement and optimization processes,” added Professor Aharoni.
Biosynthetic technologies have the potential to revolutionize production methods based on the cultivation and extraction of cannabinoid compounds for the CPG and pharmaceutical industry. However, the development of these long-awaited cannabinoid biosynthetic processes has been slowed down and challenged by several bottlenecks related to enzymatic and genetic modification resulting from the introduction of cannabis genes into fermentation systems based on cannabis. microorganisms. The discovery of a non-Cannabaceae cannabinoid-producing botanical expression system has the potential to solve and alleviate some of these problems by initiating a new toolbox of genes and enzyme machines. Using this new toolkit, Xinteza aims to engineer new cannabinoid biosynthetic pathways, in order to achieve higher yields and efficiencies, better consistency, purity and cost-effectiveness.
“This groundbreaking discovery puts Xinteza at the forefront of cannabinoid sourcing and synthesis and is creating excitement in the field,” says Alon gal, CEO of Xinteza API. “The flexibility and efficiency of this extraordinary patent-pending alternative genetic system offers solutions to some of the burning delivery issues currently plaguing our industry. We will continue to advance our research and development of the most innovative biosynthesis and potency of an array of high-enhance cannabinoids and leverage our rapidly growing library of genes, enzymes and novel molecules, while advancing collaborations with leading players in the field of biosynthesis .”
About Xinteza API
Xinteza API Ltd. is engaged in the research and discovery of a wide range of new genes and ultra-novel genetic pathways for the biosynthesis of cannabinoids and psychoactive ingredients, and the development of their bioproduction methods. Xinteza holds an exclusive license for cannabinoids and psychoactives from the Weizmann Institute of Science with research led by Prof. Asaph Aharoni and diligently built an unparalleled portfolio of dozens of intellectual property assets and related patents.
Founded in 2019 and led by a team of experienced entrepreneurs, Xinteza’s strategic partners include industry players such as IM Cannabis (NASDAQ: IMCC)(CSE: IMCC)
Xinteza’s goal is to produce a wide range of natural laboratory-produced minor and modified cannabinoids, as well as the most researched psychoactive ingredients. He aims to make the production of innovative APIs and AIs for CPGs and high-end pharmaceuticals more accessible by implementing his disruptive discoveries of new genes, genetic pathways and molecules, and removing bottlenecks and by stimulating natural production processes.
Yeda Research and Development Company Ltd. is the business arm of the Weizmann Institute of Science. Yeda currently manages approximately 500 unique patent families and has generated the highest revenue per researcher of any university technology transfer operation in the world. Over the years, Yeda has contributed to the commercialization of a number of breakthrough therapies, such as Copaxone, Rebif, Tookad®, Erbitux®, Vectibix®, Protrazza®, Humira®, and recently the CAR-T cancer therapy Yescarta ®.
About the Weizmann Institute of Science
The Weizmann Institute of Science Israel is one of the best multidisciplinary research institutions in the world. Noted for its broad exploration of natural and exact sciences, Weizmann Institute scientists advance research in the human brain, artificial intelligence, computing and encryption, astrophysics and particle physics, and s tackle diseases such as cancer, while tackling climate change through environmental, ocean and plant science.
For more informationvisit: https://xinteza.com or visit our official LinkedIn channel.
Xinteza API Ltd. – Press, Marketing, Investor Relations
E : [email protected]
Alon galCEO and co-founder
E : [email protected]
Dr. Zohar Koren, CTO and co-founder
E : [email protected]
Photo – https://mma.prnewswire.com/media/1876584/Alon_Gal_Xinteza_API_Ltd.jpg
Photo – https://mma.prnewswire.com/media/1876676/Prof_Asaph_Aharoni_Weizmann.jpg
SOURCEXinteza API Ltd.